SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of employee being let go, falling out of chair
Layoffs
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.
February 6, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
External view of Bristol Myers Squibb's office California
Earnings
BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success
Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of exclusivity for its blockbuster drugs Eliquis and Opdivo.
February 6, 2025
 · 
3 min read
 · 
Annalee Armstrong
3d render, open blue door isolated on blue background, yellow light going through the slot. Architectural design element. Modern minimal concept. Opportunity metaphor.
Business
Viracta Winds Down Business, Unable to Weather Financial Troubles
Viracta’s closure comes on the heels of its delisting from Nasdaq last month and multiple rounds of layoffs last year.
February 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
Earnings
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.
February 6, 2025
 · 
3 min read
 · 
Tristan Manalac
Businessman pulling rope trying to lift up falling graph.
Cancer
Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed
Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.
February 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Hiring collage showing HR checking applicant information
Job Trends
Hiring Outlook: Despite Challenges, January Brings Optimism for Job Market
Most employers are expecting to hire this year, according to BioSpace data and Recruitment Manager Greg Clouse, who noted that companies are looking to do more than just replace people lost to turnover.
February 6, 2025
 · 
3 min read
 · 
Angela Gabriel
Vertical collage image of zombie people arms stick pile stack crumpled dollar banknotes bills isolated on beige background stock photo
Earnings
Despite Doubled Wegovy Sales, Novo Executives Confront Analysts’ Insatiable Appetite
Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.
February 5, 2025
 · 
2 min read
 · 
Annalee Armstrong
Dollar banknote cut into pieces on a yellow background
Business
Valerio Shutters U.S. Operations, Cuts Clinical Work Due to ‘Financing Challenges’
Valerio only has cash to last three months, according to the DNA decoy specialist. The news comes less than six months after the company acquired Emglev Therapeutics to advance antibodies for autoimmune and inflammatory conditions, as well as cancers.
February 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Three women, employees walking forward on red and green dots Conceptual creative design. Coordinated approach to achieve goals and overcome obstacles. Concept of business, progress, risk, promotion
Editorial
A Lack of Women in Leadership Is the Biopharma Story That Never Ends
BioSpace Senior Editor Annalee Armstrong headed to the J.P. Morgan Healthcare Conference with a months-long story idea brewing. Unfortunately, it was one she’s written before.
February 5, 2025
 · 
4 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS